Imatinib spares cKit-expressing prostate neuroendocrine tumors, whereas kills seminal vesicle epithelial-stromal tumors by targeting PDGFR-β

Molecular Cancer Therapeutics

Volumn 16, Issue 2, 2017, Pages 365-375

  Jachetti, Elena ^a   Rigoni, Alice ^a   Bongiovanni, Lucia ^b   Arioli, Ivano ^a   Botti, Laura ^a   Parenza, Mariella ^a   Cancila, Valeria ^b   Chiodoni, Claudia ^a   Festinese, Fabrizio ^a   Bellone, Matteo ^c   Tardanico, Regina ^d   Tripodo, Claudio ^b   Colombo, Mario P ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CROMOGLYCATE DISODIUM; IMATINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; TYROSINE KINASE RECEPTOR; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; PROTEIN KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWNSTREAM PROCESSING; DRUG INHIBITION; DRUG TARGETING; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MALE; MAST CELL; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; ONCOGENE C KIT; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; SEMINAL VESICLE; SIGNAL TRANSDUCTION; THERAPY EFFECT; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; NEUROENDOCRINE TUMORS; PATHOLOGY; PROSTATIC NEOPLASMS; TRANSGENIC MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMATINIB MESYLATE; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, TRANSGENIC; NEUROENDOCRINE TUMORS; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SEMINAL VESICLES; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85012005462     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-16-0466     Document Type: Article

References (50)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Dickinson SI. Premalignant and malignant prostate lesions: pathologic review. Cancer Control 2010;17:214-22.
3. Komiya A, Suzuki H, Imamoto T, Kamiya N, Nihei N, Naya Y, et al. Neuroendocrine differentiation in the progression of prostate cancer. Int J Urol 2009;16:37-44.
4. Terry S, Beltran H. The many faces of neuroendocrine differentiation in prostate cancer progression. Front Oncol 2014;4:60.
5. Greenberg NM, DeMayo F, Finegold MJ,MedinaD, Tilley WD, Aspinall JO, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995;92:3439-43.
6. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004;64:2270-305.
7. Chiaverotti T, Couto SS, Donjacour A, Mao JH, Nagase H, Cardiff RD, et al. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol 2008;172:236-46.
8. Huss WJ, Gray DR, Tavakoli K, Marmillion ME, Durham LE, Johnson MA, et al. Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model. Neoplasia 2007; 9:938-50.
9. Tani Y, Suttie A, Flake GP, Nyska A, Maronpot RR. Epithelial-stromal tumor of the seminal vesicles in the transgenic adenocarcinoma mouse prostate model. Vet Pathol 2005;42:306-14.
10. Yeh IT, Reddick RL, Kumar AP. Malignancy arising in seminal vesicles in the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Prostate 2009;69:755-60.
11. Stamatakos M, Tsaknaki S, Kontzoglou K, Gogas J, Kostakis A, Safioleas M. Phylloides tumor of the breast: A rare neoplasm, though not that innocent. Int Semin Surg Oncol 2009;6:6.
12. Tan BY, Acs G, Apple SK, Badve S, Bleiweiss IJ, Brogi E, et al. Phyllodes tumours of the breast: A consensus review. Histopathology 2016; 68:5-21.
13. Shabaik A. Nonepithelial tumors and tumor-like lesions of the prostate gland. Crit Rev Clin Lab Sci 2003;40:429-72.
14. Reikie BA, Yilmaz A, Medlicott S, Trpkov K.Mixed epithelial-stromal tumor (MEST) of seminal vesicle: A proposal for unified nomenclature. Adv Anat Pathol 2015;22:113-20.
15. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999;13:1382-97.
16. Chang DZ, Ma Y, Ji B, Wang H, Deng D, Liu Y, et al. Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma. Clin Cancer Res 2011;17:7015-23.
17. Ma Y, Hwang RF, Logsdon CD, Ullrich SE. Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer. Cancer Res 2013;73:3927-37.
18. Pittoni P, Tripodo C, Piconese S, Mauri G, Parenza M, Rigoni A, et al. Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. Cancer Res 2011;71:5987-97.
19. Thompson PJ, Hanson JM, Morley J. Asthma, mast cells, and sodium cromoglycate. Lancet 1983;2:848-9.
20. Masso-Valles D, Jauset T, Serrano E, Sodir NM, Pedersen K, Affara NI, et al. Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma. Cancer Res 2015;75:1675-81.
21. Galli SJ, Borregaard N, Wynn TA. Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. Nat Immunol 2011;12:1035-44.
22. Quintas-Cardama A, Kantarjian H, Cortes J. Imatinib and beyond-exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol 2009;6:535-43.
23. Joensuu H, DeMatteo RP. The management of gastrointestinal stromal tumors: A model for targeted andmultidisciplinary therapy of malignancy. Annu Rev Med 2012;63:247-58.
24. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
25. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-45.
26. Grimbaldeston MA, Chen CC, Piliponsky AM, Tsai M, Tam SY, Galli SJ. Mast cell-deficientW-sash c-kit mutant KitW-sh/W-sh mice as a model for investigating mast cell biology in vivo. Am J Pathol 2005;167:835-48.
27. Mauri G, Jachetti E, Comuzzi B, Dugo M, Arioli I, Miotti S, et al. Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers. Oncotarget 2015;7:3905-20.
28. Mazzoleni S, Jachetti E, Morosini S, Grioni M, Piras IS, Pala M, et al. Gene signatures distinguish stage-specific prostate cancer stem cells isolated from transgenic adenocarcinoma of the mouse prostate lesions and predict the malignancy of human tumors. Stem Cells Transl Med 2013;2:678-89.
29. Gri G, Piconese S, Frossi B, Manfroi V, Merluzzi S, Tripodo C, et al. CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity 2008;29: 771-81.
30. Foger N, Jenckel A, Orinska Z, Lee KH, Chan AC, Bulfone-Paus S. Differential regulation ofmast cell degranulation versus cytokine secretion by the actin regulatory proteins Coronin1a and Coronin1b. J Exp Med 2011; 208:1777-87.
31. Tai S, Sun Y, Squires JM, Zhang H, Oh WK, Liang CZ, et al. PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate 2011;71:1668-79.
32. Lennartsson J, Ronnstrand L. Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol Rev 2012;92:1619-49.
33. Demoulin JB, Essaghir A. PDGF receptor signaling networks in normal and cancer cells. Cytokine Growth Factor Rev 2014;25:273-83.
34. Feakins RM, Wells CA, Young KA, Sheaff MT. Platelet-derived growth factor expression in phyllodes tumors and fibroadenomas of the breast. Hum Pathol 2000;31:1214-22.
35. Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP. Treating patients with metastatic castration resistant prostate cancer: A comprehensive review of available therapies. J Urol 2015;194:1537-47.
36. Di Lorenzo G, Autorino R, D'Armiento FP, Mignogna C, De Laurentiis M, De Sio M, et al. Expression of proto-oncogene c-kit in high risk prostate cancer. Eur J Surg Oncol 2004;30:987-92.
37. Simak R, Capodieci P, Cohen DW, Fair WR, Scher H, Melamed J, et al. Expression of c-kit and kit-ligand in benign andmalignant prostatic tissues. Histol Histopathol 2000;15:365-74.
38. Terada T. Small-cell neuroendocrine carcinoma of the prostate: incidence and a report of four cases with an examination of KIT and PDGFRA. Prostate 2012;72:1150-6.
39. Patil DT, Rubin BP. Genetics of gastrointestinal stromal tumors: A heterogeneous family of tumors? Surg Pathol Clin 2015;8:515-24.
40. Tetsu O, Phuchareon J, Chou A, Cox DP, Eisele DW, Jordan RC.Mutations in the c-Kit gene disrupt mitogen-activated protein kinase signaling during tumor development in adenoid cystic carcinoma of the salivary glands. Neoplasia 2010;12:708-17.
41. Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med 2016;22:298-305.
42. Smith BA, Sokolov A, Uzunangelov V, Baertsch R, Newton Y, Graim K, et al. A basal stem cell signature identifies aggressive prostate cancer phenotypes. Proc Natl Acad Sci U S A 2015;112:E6544-52.
43. Rosenberg A, Mathew P. Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor. Expert Opin Investig Drugs 2013;22:787-94.
44. Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, et al. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res 2007;13:5816-24.
45. Ko YJ, Small EJ, Kabbinavar F, Chachoua A, Taneja S, Reese D, et al. Amultiinstitutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin Cancer Res 2001;7:800-5.
46. Rao K, Goodin S, Levitt MJ, Dave N, ShihWJ, Lin Y, et al. A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate 2005;62:115-22.
47. Vogelhuber M, Feyerabend S, Stenzl A, Suedhoff T, Schulze M, Huebner J, et al. Biomodulatory treatment of patients with castration-resistant prostate cancer: A phase II study of imatinib with pioglitazone, etoricoxib, dexamethasone and low-dose treosulfan. Cancer Microenviron 2015;8: 33-41.
48. Hofer MD, Fecko A, Shen R, Setlur SR, Pienta KG, Tomlins SA, et al. Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. Neoplasia 2004;6:503-12.
49. Fain JS, Cosnow I, King BF, Zincke H, Bostwick DG. Cystosarcoma phyllodes of the seminal vesicle. Cancer 1993;71:2055-61.
50. Abe H, Nishimura T, Miura T, Uchikoba T, Ohno T, Ishikawa N, et al. Cystosarcoma phyllodes of the seminal vesicle. Int J Urol 2002;9:599-601.